{{Infobox company
| name             = Ranbaxy Laboratories Limited
| logo             = Ranbaxy Logo.svg
| logo_size        =
| caption          =
| type             = 
| fate             = 被太阳制药收购
| predecessor      =
| successor        = [[太阳制药|太阳制药]]
| foundation       = {{Start date|1961}}
| founders         = Ranbir Singh <br/> Gurbax Singh
| location_city    = [[古尔冈|古尔冈]]
| location_country = [[印度|印度]]
| locations        =
| area_served      =
| key_people       = 
| industry         = [[制药|制药]]
| products         =
| services         =
| revenue          =
| operating_income =
| net_income       =
| aum              = <!-- Only used with financial services companies -->
| assets           =
| equity           =
| owner            =
| num_employees    = 10,983 （2012）<ref name="2012report">{{cite web|url=http://www.ranbaxy.com/wp-content/uploads/2013/03/ranbaxy_annual_report_2012.pdf|title=Annual Report 2012|publisher=Ranbaxy Laboratories Limited|archiveurl=https://web.archive.org/web/20131105153730/http://www.ranbaxy.com/wp-content/uploads/2013/03/ranbaxy_annual_report_2012.pdf|archivedate=2013-11-05|access-date=2020-10-14|dead-url=yes}}</ref>

}}
'''兰伯西实验室有限公司'''（Ranbaxy Laboratories Limited）是1961年成立的一家印度制药公司，它在1973年上市，2008年[[第一三共|第一三共]]获得其控股权<ref name="BB20180611merger">{{cite web |last1=Matsuyama |first1=Kanoko |last2=Chatterjee |first2=Saikat |title=Daiichi to Take Control of Ranbaxy for $4.6 Billion (Update3) - Bloomberg |url=https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aMiwVweIVD60&refer=japan |website=Bloomberg.com |publisher=Bloomberg LP |accessdate=2018-08-11 |archiveurl=https://web.archive.org/web/20141202122035/http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aMiwVweIVD60&refer=japan |archivedate=2014-12-02 |date=June 11, 2008 |dead-url=no }}</ref>，2014年被[[太阳制药|太阳制药]]收购，后者因此成为印度最大的制药公司。

==问题==

自2004年开始，该公司就多次因伪造药物测试报告而被[[美国食品和药物管理局|美国食品和药物管理局]]调查<ref name=eban2013>{{Cite news | url=http://fortune.com/2013/05/15/dirty-medicine/ | title=Dirty Medicine | first=Katherine | last=Eban | publisher=Fortune | date=2013-05-15 | access-date=2018-02-06 | archive-date=2021-04-08 | archive-url=https://web.archive.org/web/20210408225044/https://fortune.com/2013/05/15/dirty-medicine/ | dead-url=no }} — an in-depth investigation of Ranbaxy Laboratories</ref><ref>{{cite news | title = FDA Takes New Regulatory Action Against Ranbaxy's Paonta Sahib Plant in India. Agency halts review of drug applications from plant due to evidence of falsified data; invokes Application Integrity Policy | date = 25 February 2009 | publisher = [[Food_and_Drug_Administration|Food and Drug Administration]] | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149532.htm | work = Press Announcement | access-date = 1 June 2013 | quote = The FDA's investigations revealed a pattern of questionable data raising significant questions regarding the reliability of certain applications, and this warrants applying the Application Integrity Policy, said Deborah Autor, director of CDER's Office of Compliance. | archive-date = 2017-01-18 | archive-url = https://web.archive.org/web/20170118091038/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149532.htm | dead-url = no }}</ref>。2012年它又多次在荷兰等其他国家召回存在杂质的药物<ref>{{cite web |url=http://www.gezondheidskrant.nl/40871/knmp-waarschuwt-voor-verontreinigde-tabletten/ |title=KNMP waarschuwt voor verontreinigde tabletten — |language=nl |publisher=Gezondheidskrant.nl |access-date=2020-10-14 |archive-date=2016-03-24 |archive-url=https://web.archive.org/web/20160324200445/http://www.gezondheidskrant.nl/40871/knmp-waarschuwt-voor-verontreinigde-tabletten/ |dead-url=no }}</ref><ref>[https://www.forbes.com/sites/larryhusten/2012/11/29/following-earlier-recall-ranbaxy-halts-manufacturing-atorvastatin/ Following Earlier Recall, Ranbaxy Halts Manufacturing Atorvastatin] {{Wayback|url=https://www.forbes.com/sites/larryhusten/2012/11/29/following-earlier-recall-ranbaxy-halts-manufacturing-atorvastatin/ |date=20201016063441 }}. Forbes.</ref><ref>{{cite news|title = Ranbaxy Halts Production of Generic Lipitor|date = 29 November 2012|url = https://online.wsj.com/news/articles/SB10001424127887323751104578149383396925280|last = Loftus|first = Peter|work = [[The_Wall_Street_Journal|The Wall Street Journal]]|access-date = 10 March 2014|archivedate = 2014-02-26|archiveurl = https://web.archive.org/web/20140226173706/http://online.wsj.com/news/articles/SB10001424127887323751104578149383396925280|dead-url = no}}{{Subscription required}}</ref>。

2013年5月，它因制造、销售假药及伪造临床数据而在美国被判有罪<ref name='13-542'>{{cite news | title = Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, cGMP Violations and False Statements to the FDA | date = 13 May 2013 | publisher = Office of Public Affairs | url = http://www.justice.gov/opa/pr/2013/May/13-civ-542.html | work = [[United_States_Department_of_Justice|The United States Department of Justice]] | access-date = 1 January 2018 | archive-date = 2014-08-12 | archive-url = https://web.archive.org/web/20140812064721/http://www.justice.gov/opa/pr/2013/May/13-civ-542.html | dead-url = no }}</ref><ref>{{Cite web |url=https://www.bbc.com/news/world-asia-india-22520953 |title=India drug firm pays record US fine |date=2013-05-14 |website=BBC News |language=en-GB |access-date=2018-01-03 |archive-date=2019-12-15 |archive-url=https://web.archive.org/web/20191215173231/https://www.bbc.com/news/world-asia-india-22520953 |dead-url=no }}</ref>。同年9月，该公司又被曝存在严重卫生问题，这包括员工厕后不洗手、药物中存在人类毛发等<ref>{{Cite web|url=https://www.thehindubusinessline.com/companies/fda-finds-quality-process-lapses-at-ranbaxy-plant/article20662492.ece1|title=FDA finds quality, process lapses at Ranbaxy plant|first=Our|last=Bureau|website=@businessline|access-date=2020-10-14|archive-date=2021-01-18|archive-url=https://web.archive.org/web/20210118145644/https://www.thehindubusinessline.com/companies/fda-finds-quality-process-lapses-at-ranbaxy-plant/article20662492.ece1|dead-url=no}}</ref><ref>{{Cite web |url=http://www.niticentral.com/2013/09/18/ranbaxy-import-ban-usfda-found-suspected-hair-oil-in-tablets-134445.html |title=Ranbaxy import ban: US FDA found suspected hair, oil in tablets |access-date=2020-10-14 |archive-date=2013-09-23 |archive-url=https://web.archive.org/web/20130923030519/http://www.niticentral.com/2013/09/18/ranbaxy-import-ban-usfda-found-suspected-hair-oil-in-tablets-134445.html |dead-url=yes }}</ref>。因此FDA决定禁止该公司在达到美国标准前于其[[莫哈里|莫哈里]]工厂生产FDA管制药物。<ref>{{cite news | title = FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy's Mohali, India, plant and issues import alert | date = 2013-09-16 | publisher = [[Food_and_Drug_Administration|Food and Drug Administration]] | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm368445.htm | work = Press Announcement | access-date = 2013-10-08 | quote = The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.’s facility in Mohali, India. The firm will remain on the import alert until the company complies with U.S. drug manufacturing requirements, known as current good manufacturing practices (CGMP). | archive-date = 2017-01-12 | archive-url = https://web.archive.org/web/20170112223012/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm368445.htm | dead-url = no }}</ref>

==参考文献==
{{reflist|colwidth=30em}}

==外部链接==

*[https://web.archive.org/web/20050916092549/http://www.ranbaxy.com/ 官方网站存档]

[[Category:印度制药公司|Category:印度制药公司]]
[[Category:1961年成立的公司|Category:1961年成立的公司]]
[[Category:2014年結業公司|Category:2014年結業公司]]